FDA approves Nuvalent's cancer drug, a week after GSK closed $10.6B buyout

July 22, 2026 02:21 PM EDT PharmaFDA+ FDA ap­proves Nu­va­len­t's can­cer drug, a week af­ter GSK closed $10.6B buy­out Kyle LaHucik Biotech Correspondent GSK’s $10.6 bil­lion ac­qui­si­tion of Nu­va­lent is de­liv­er­ing sur­pris­ing­ly ear­ly re­sults. The FDA on Wednes­day ap­proved one of Nu­va­lent’s lung can­cer med­i­cines … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER